Institution
Bethesda Hospital
Healthcare•Ambur, Tamil Nadu, India•
About: Bethesda Hospital is a healthcare organization based out in Ambur, Tamil Nadu, India. It is known for research contribution in the topics: Population & Helicobacter pylori. The organization has 386 authors who have published 472 publications receiving 15193 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, a tailored axillary surgery (TAS) was proposed to reduce the axillary tumor volume in patients with clinically node-positive breast cancer to the point where radiotherapy can control it.
16 citations
••
TL;DR: Moderate temporal heterogeneity between paired tumor samples is shown with the acquisition of new mutations and identification of genes possibly related to therapy resistance in DLBCL.
Abstract: Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally assess the mutational evolution and to identify gene mutations specific for relapse samples from patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A minority of the mutations detected in the primary sample (median 7.6%, range 4.8⁻66.2%) could not be detected in the matching relapse sample. Relapsed DLBCL samples showed a mild increase of mutations (median 12.5%, range 9.4⁻87.6%) as compared to primary tumor biopsies. We identified 264 genes possibly related to therapy resistance, including tyrosine kinases (n = 18), (transmembrane) glycoproteins (n = 73), and genes involved in the JAK-STAT pathway (n = 7). Among the potentially resistance related genes were PIM1, SOCS1, and MYC, which have been reported to convey a risk for treatment failure. In conclusion, we show modest temporal heterogeneity between paired tumor samples with the acquisition of new mutations and identification of genes possibly related to therapy resistance. The mutational evolution could have implications for treatment decisions and development of novel targeted drugs.
16 citations
••
TL;DR: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment with nortriptyline or venlafaxine among older patients with depression.
Abstract: Background: Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines for dose adaptations based on the CYP2D6 genotype have been developed. The CYP2D6 Screening Among Elderly (CYSCE) trial is designed to address the potential health and economic value of genotyping for CYP2D6 in optimizing dose-finding of nortriptyline and venlafaxine. Methods/Design: In a pragmatic randomized controlled trial, patients diagnosed with a major depressive disorder according to the DSM-IV and aged 60 years or older will be recruited from psychiatric centers across the Netherlands. After CYP2D6 genotyping determined in peripheral blood obtained by finger-prick, patients will be grouped into poor, intermediate, extensive, or ultrarapid metabolizers. Patients with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice is communicated to the treating physician, or to a control group in which patients receive care as usual. Additionally, an external reference group of patients with the extensive metabolizer genotype is included. Primary outcome in all groups is time needed to obtain an adequate blood level of the antidepressant drug. Secondary outcomes include adverse drug reactions measured by a shortened Antidepressant Side-Effects Checklist (ASEC), and cost-effectiveness of the screening. Discussion: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment with nortriptyline or venlafaxine among older patients with depression.
15 citations
••
University of Cologne1, University Medical Center Freiburg2, Martin Luther University of Halle-Wittenberg3, Ludwig Maximilian University of Munich4, Augsburg College5, University of Rostock6, Paracelsus Private Medical University of Salzburg7, University of Hamburg8, Leipzig University9, Bethesda Hospital10, RWTH Aachen University11, University of Bern12, Technische Universität München13, University of Würzburg14, University of Düsseldorf15, Ruhr University Bochum16, University of Marburg17, Medical University of Vienna18, Innsbruck Medical University19, Georgia Regents University20
TL;DR: This international multicenter analysis of surgical techniques for mandibular repositioning shows that different surgical methods seem to work as comparable, safe, and reliable procedures in everydays clinical practise.
Abstract: Orthognathic surgery has always been a classical focus of maxillofacial surgery. Since more than 100 years, various surgical techniques for mandibular repositioning have been developed and clinically tested. Since the establishment of plate and screw osteosynthesis, orthognathic surgery became more stable and safe. Nowadays, different surgical methods for mobilising the mandible are existing. This international multicenter analysis (n = 51 hospitals) is providing first evidence based data for the current use of different surgical methods. The dominating techniques were Obwegeser/dal Pont (61%) followed by Hunsuck/Epker (37%) and Perthes/Schlossmann (29%). The main osteosynthesis materials were plates (82%), bicortical screws (23.5%), or a combination of both (5.9%). 47% of all centers reported to use several surgical methods at the same time, depending on the anatomical problem and the surgeon's preference. This shows that different surgical methods seem to work as comparable, safe, and reliable procedures in everydays clinical practise. On this basis, further prospective studies could evaluate possible advantages for our patients.
15 citations
••
TL;DR: Although the R389G polymorphism of the beta1-adrenoceptor gene did not influence resting HR or BP in untreated OSA patients, it may modify the beneficial effects of CPAP therapy on these parameters.
Abstract: OSA (obstructive sleep apnoea) stimulates sympathetic nervous activity and elevates resting HR (heart rate) and BP (blood pressure). In the present study in a cohort of 309 untreated OSA patients, the resting HR and BP during the daytime were correlated with AHI (apnoea/hypopnea index) and compared with patients with R389R (n = 162), R389G (n = 125) and G389G (n = 22) genotypes of the β1-adrenoreceptor R389G polymorphism. We analysed the impact of the genotype on the decline of HR and BP in a subgroup of 148 patients (R389R, n = 86; R389G, n = 54; G389G, n = 8) during a 6-month follow-up period under CPAP (continuous positive airway pressure) therapy during which cardiovascular medication remained unchanged. In untreated OSA patients, we found an independent relationship between AHI and resting HR (β = 0.096, P < 0.001), systolic BP (β = 0.09, P = 0.021) and diastolic BP (β = 0.059, P = 0.016). The resting HR/BP, however, did not differ among carriers with the R389R, R389G and G389G genotypes. CPAP therapy significantly reduced HR [− 2.5 (− 1.1 to − 4.0) beats/min; values are mean difference (95 % confidence intervals)] and diastolic BP [− 3.2 (− 1.5 to − 5.0) mmHg]. The decline in HR was more significantly pronounced in the R389R group compared with the Gly 389 carriers [− 4.1 (− 2.3 to − 5.9) beats/min (P < 0.001) compared with − 0.2 (2.1 to − 2.6) beats/min (P = 0.854) respectively; Student’s t test between groups, P = 0.008]. Diastolic BP was decreased significantly (P < 0.001) only in Gly 389 carriers (R389G or G389G) compared with R389R carriers [− 5.0 (− 2.3 to − 7.6) mmHg compared with − 2.0 (0.4 to − 4.3) mmHg respectively]. ANOVA revealed a significant difference (P = 0.023) in HR reduction between the three genotypes [− 4.1 (+ 8.4) beats/ min for R389R, − 0.5 (+ 9.3) beats/min for R389G and + 1.9 (+ 7.2) beats/min for G389G]. In conclusion, although the R389G polymorphism of the β1-adrenoceptor gene did not influence resting HR or BP in untreated OSA patients, it may modify the beneficial effects of CPAP therapy on these parameters.
15 citations
Authors
Showing all 387 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jennie Ponsford | 73 | 393 | 18379 |
Peter J. Stern | 53 | 235 | 8622 |
Roger Hart | 46 | 154 | 7065 |
Glynda J. Kinsella | 40 | 120 | 5752 |
Jacinta Douglas | 39 | 180 | 4737 |
Gabriela Möslein | 36 | 112 | 6057 |
Pamela Claire Snow | 36 | 142 | 4496 |
Michael Denkinger | 34 | 147 | 3214 |
Thomas Daikeler | 30 | 141 | 3309 |
John Olver | 25 | 103 | 3189 |
J. C. Thijs | 24 | 46 | 2194 |
Daniel Navot | 24 | 56 | 2705 |
Bernd Sanner | 23 | 102 | 2652 |
Ulrike Nitz | 22 | 98 | 4068 |
Dries Testelmans | 22 | 92 | 2100 |